Carvedilol versus other β-blockers in heart failure

Expert Opinion on Investigational Drugs

Volumn 10, Issue 5, 2001, Pages 971-980

  Doggrell, S A ^a  

^a Doggrell Biomedical Communication   (New Zealand)

Author keywords

Bisoprolol; Carvedilol; Clinical trials; Heart failure; Metoprolol

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELIPROLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MATRIX PROTEIN; METOPROLOL; OXYGEN RADICAL; PLACEBO; PRAZOSIN; SPIRONOLACTONE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORBIDITY; MORTALITY; MULTICENTER STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STANDARD;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; PROPANOLAMINES;

EID: 0035022078     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.5.971     Document Type: Article

References (40)

1. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol
2. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: Effects of beta-receptor blockade
3. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart
4. Antiarrhythmic drug carvedilol inhibits HERG potassium channels
5. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
6. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
7. Safety and efficacy of carvedilol in severe heart failure
8. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
9. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise
10. Carvedilol inhibits clinical progression in patients with symptoms of heart failure
11. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
12. Australian-New Zealand heart failure research collaborative group: Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease
13. Australian-New Zealand heart failure research collaborative group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart disease due to ischaemic heart disease
14. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
15. Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease
16. Neurohumoral prediction of benefit for carvedilol in ischaemic left ventricular dysfunction
17. Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure
18. Beta-blockage therapy in chronic heart failure: Diastolic function and mitral regugitation improvement by carvedilol
19. Pulmonary function, cardiac function and exercise capacity in a follow-up of patients with congestive heart failure with carvedilol
20. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: Double-blind, randomized, placebo-controlled study
21. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial
22. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
23. The Metroprolol In Dilated Cardiomyopathy (MDC) trial study group: 3-year follow-up of patients randomised in the metoprolol cardiomyopathy trial
24. Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety and effect on left ventricular ejection fraction
25. The Merit-HF Investigators: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
26. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)
27. Antiremodeling effects on the left ventricle during beta-blockade with metoprol in the treatment of chronic heart failure
28. Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
29. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure
30. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol
31. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
32. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
33. The Cibis Investigators and Committees: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)
34. The Cibis II Investigators: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
35. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties
36. Usefulness of bucindolol in congestive heart failure
37. Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy
38. The Best Steering Committee: Design of the Beta-Blocker Evaluation Survival Trial (BEST)
39. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure
40. The effect of spironolactone on morbidity and mortality in patients with severe heart failure